Broad Institute

AUGUST 7, 2023

A surprising role STING (short for stimulator of interferon genes) is considered one of the major factors that triggers the immune response in the context of infection, autoimmunity, and cancer. Food and Drug Administration has not approved any STING agonist thus far, although multiple clinical trials are currently underway.

Regulations 91

Regulations Clinical Trials Engineering Science 91

Drug Target Review

FEBRUARY 28, 2024

Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers. gammadelta T cells link innate and adaptive immune responses. Cells 9(40):800 (2020).

Therapies 105

Therapies Engineering Molecular Biology Science 105

Codon

FEBRUARY 13, 2024

1 Yet even after more than two decades of research, media hype, and dozens of clinical trials and biotech start-ups that have come and gone, phage therapy has not scaled. No phage-based therapeutic has reached the latter stages of the clinical trial pipeline (where promising results lead to an expanded trial involving thousands of patients).

Therapies 124

Therapies Virus DNA Clinical Trials 124

The Pharma Data

SEPTEMBER 17, 2020

The Elecsys Anti-SARS-CoV-2 serology test can be used to quantitatively measure antibodies in people who have been exposed to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and can play an important part in characterising a vaccine-induced immune response. said Thomas Schinecker, CEO Roche Diagnostics.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

Dark Matter Blog

JULY 16, 2021

The only subject in school that held my interest was biology. As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. I wanted to use molecular biology to create drugs. As any good idea tends to have a long life, Ad-IFN is currently in a phase 3 clinical trial in mesothelioma patients.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

Drug Target Review

DECEMBER 12, 2024

Aside from the ethical questions they raise, ESCs are in limited supply and are generally recognised as foreign by the recipient patients immune system. This can trigger an immune response that causes the body to reject these therapeutic cells. Progress in molecular biology and translational science [Internet].

Therapies 59

Therapies DNA Molecular Biology Immune Response 59